A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: Successfully treated with combination therapy

International Journal of Clinical Pharmacy

Volumn 33, Issue 5, 2011, Pages 726-729

  Kumar, Nawin ^a   Sinha, Prabhat Kumar ^a   Pandey, Krishna ^a   Verma, Neena ^b   Lal, Chandra Shekhar ^c   Ranjan, Alok ^d   Verma, Rakesh Bihari ^e   Das, Pradeep ^f  

^a RMRIMS (ICMR)   (India)

^b Division of Pathology   (India)

^c Division of Biochemistry   (India)

^d Division of Epidemiology and Biostatistics   (India)

^e Division of Biostatistics   (India)

^f Division of Molecular Biology   (India)

Author keywords

Amphotericin B; Combination therapy; Liposomal amphotericin B; Miltefosine; Paromomycin; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; HEMOGLOBIN; MILTEFOSINE; PAROMOMYCIN;

ADULT; ANEMIA; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; COMBINATION CHEMOTHERAPY; DETERIORATION; ENDEMIC DISEASE; FEVER; FOLLOW UP; HEPATOSPLENOMEGALY; HUMAN; INDIA; LEISHMANIA DONOVANI; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MONOTHERAPY; PRIORITY JOURNAL; RELAPSE; SINGLE DRUG DOSE; SPLEEN BIOPSY; THROMBOCYTOPENIA; VISCERAL LEISHMANIASIS; WEAKNESS;

ADULT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HUMANS; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; RECURRENCE;

EID: 83255185225     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-011-9544-8     Document Type: Article

References (10)

1. Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a sub-clinical form of visceral leishmaniasis. J Infect Dis. 1986;154:1003-11. (Pubitemid 17199035)
2. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India. Clinical Infect Dis. 2000;31(4):1104-7.
3. Jha TK, Giri YN, Singh TK, Jha S. Use of amphotericin-B in drug- resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Hyg. 1995;52:536-8.
4. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral Leishmaniasis in India. New England J Med. 2007;356(25):2571-81. (Pubitemid 46961002)
5. Jochim RC, Teixeira C. Leishmania commandeers the host inflammatory response through neutrohils. Trends Parasitol. 2009;25(4):145-7.
6. Alvar J, Aparicio P, Aseffa A, Boer MD, Cañavate C, Jean-Pierre Dedet, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334-59. (Pubitemid 351555511)
7. Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis. 2009;48(2): e16-22.
8. Seifert K, Perez-Victoria FJ, Stettler M, Sanchez-Canete MP, Castanys S, Gamarro F, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistant that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents. 2007;30(3):229-35. (Pubitemid 47135625)
9. Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, et al. Ambisome plus miltefosine for Indian patients with kalaazar. Trans R Soc Trop Med Hyg. 2010;105(2):115-7.
10. Sundar S, Sinha PK, Rai M, Verma DK, Kumar N, Alam S, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, noninferiority, randomised controlled trial. Lancet. 2011;377(9764): 477-86.